Researchers at the Telethon Kids Institute have been awarded $4.6 million in national funding from the National Health and Medical Research Council (NHMRC) and Medical Research Future Fund (MRFF) to help support child health research. ...

• 1. Telethon Kids Institute
• News & Events
• News & Events at Telethon Kids
• 2020
• May

There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• September 2020

This review explores computational strategies to yield biological insight into the processes involved in the immunotherapeutic response ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• June 2019

The status and associated factors of the health-related quality of life of non-small-cell lung cancer patients under targeted anti-cancer therapy have not been investigated. Self-management and coping style have been proven to be closely related to patients’ health-related quality of life. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• November 2022

Oral targeted antineoplastic drugs (OTADs) are becoming more and more acceptable for lung cancer treatment due to their advantages such as the convenience of administration and milder side effects. However, medication adherence represents a major issue for prolonged OTAD treatment. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• April 2022

Predicting treatment response or survival of cancer patients remains challenging in immuno-oncology. Efforts to overcome these challenges focus, among others, on the discovery of new biomarkers. Despite advances in cellular and molecular approaches, only a limited number of candidate biomarkers eventually enter clinical practice. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• May 2021

Recurrences frequently occur following surgical removal of primary tumors. In many cancers, adjuvant therapies have limited efficacy. Surgery provides access to the tumor microenvironment, creating an opportunity for local therapy, in particular immunotherapy, which can induce local and systemic anti-cancer effects. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• July 2023

Immunotherapies have revolutionized cancer treatment. In particular, immune checkpoint therapy (ICT) leads to durable responses in some patients with some cancers. However, the majority of treated patients do not respond. Understanding immune mechanisms that underlie responsiveness to ICT will help identify predictive biomarkers of response and develop treatments to convert non-responding patients to responding ones. ICT primarily acts at the level of adaptive immunity. The specificity of adaptive immune cells, such as T and B cells, is determined by antigen-specific receptors. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• October 2020